Variables | Total population [n (%), n = 1593] | Development set [n (%), n = 1186] | Validation set [n (%), n = 407] |
---|---|---|---|
Age [median (IQRa)] | 67.0 (57.0, 77.0) | 68.0 (57.0, 77.0) | 66.0 (55.0, 77.0) |
≤65 | 715 (44.9) | 520 (43.8) | 195 (47.9) |
66–80 | 644 (40.4) | 492 (41.5) | 152 (37.3) |
> 80 | 234 (14.7) | 174 (14.7) | 60 (14.7) |
Sex | |||
Male | 1032 (64.8) | 785 (66.2) | 247 (60.7) |
Female | 561 (35.2) | 401 (33.8) | 160 (39.3) |
Race | |||
White | 1014 (63.7) | 763 (64.3) | 251 (61.7) |
Black | 240 (15.1) | 181 (15.3) | 59 (14.5) |
Other | 339 (21.3) | 242 (20.4) | 97 (23.8) |
Tumor location | |||
Cardia | 269 (16.9) | 213 (18.0) | 56 (13.8) |
Non-cardia | 998 (62.6) | 738 (62.2) | 260 (63.9) |
Overlapping lesion | 182 (11.4) | 128 (10.8) | 54 (13.3) |
Stomach, NOSb | 144 (9.0) | 107 (9.0) | 37 (9.1) |
Tumor size (mm) [median (IQR)] | 55.0 (40.0, 80.0) | 55.0 (40.0, 80.0) | 58.0 (40.0, 80.0) |
≤30 | 230 (14.4) | 172 (14.5) | 58 (14.3) |
31–50 | 466 (29.3) | 343 (28.9) | 123 (30.2) |
>50 | 897 (56.3) | 671 (56.6) | 226 (55.5) |
Pathological subtype | |||
Intestinal type | 317 (19.9) | 219 (18.5) | 98 (24.1) |
Diffuse type | 167 (10.5) | 106 (8.9) | 61 (15.0) |
Adenocarcinoma, NOS | 959 (60.2) | 754 (63.6) | 205 (50.4) |
Other adenocarcinoma | 150 (9.4) | 107 (9.0) | 43 (10.6) |
Grade | |||
Grade1/2 | 425 (26.7) | 311 (26.2) | 114 (28.0) |
Grade3/4 | 1168 (73.3) | 875 (73.8) | 293 (72.0) |
T stage (AJCCc 7th) | |||
T1 | 73 (4.6) | 55 (4.6) | 18 (4.4) |
T2 | 79 (5.0) | 49 (4.1) | 30 (7.4) |
T3 | 519 (32.6) | 409 (34.5) | 110 (27.0) |
T4a | 577 (36.2) | 402 (33.9) | 175 (43.0) |
T4b | 345 (21.7) | 271 (22.8) | 74 (18.2) |
N stage (AJCC 7th) | |||
N0 | 202 (12.7) | 142 (12.0) | 60 (14.7) |
N1 | 706 (44.3) | 522 (44.0) | 184 (45.2) |
N2 | 458 (28.8) | 349 (29.4) | 109 (26.8) |
N3 | 227 (14.2) | 173 (14.6) | 54 (13.3) |
Metastatic site(s) | |||
Distant LN(s)d | 276 (17.3) | 208 (17.5) | 68 (16.7) |
Viscera | 1121 (70.4) | 839 (70.7) | 282 (69.3) |
Viscera plus distant LN(s) | 118 (7.4) | 96 (8.1) | 22 (5.4) |
Distant metastasis, NOS | 78 (4.9) | 43 (3.6) | 35 (8.6) |
Gastrectomy | |||
Partial gastrectomy | 808 (50.7) | 612 (51.6) | 196 (48.2) |
Near-total or total gastrectomy | 361 (22.7) | 278 (23.4) | 83 (20.4) |
Gastrectomy, NOS | 424 (26.6) | 296 (25.0) | 128 (31.4) |
No. of regional LN(s) examined [median (IQR)] | 13 (6, 21) | 12 (6, 20) | 14 (7, 22) |
≤10 | 660 (41.4) | 518 (43.7) | 142 (34.9) |
>10 | 933 (58.6) | 668 (56.3) | 265 (65.1) |
Surgery to other site(s) or node(s) | |||
Yes | 404 (25.4) | 309 (26.1) | 95 (23.3) |
No | 1189 (74.6) | 877 (73.9) | 312 (76.7) |
Chemotherapy | |||
Yes | 802 (50.3) | 579 (48.8) | 223 (54.8) |
No/Unknown | 791 (49.7) | 607 (51.2) | 184 (45.2) |
Radiotherapy | |||
Yes | 254 (15.9) | 192 (16.2) | 62 (15.2) |
No/Unknown | 1339 (84.1) | 994 (83.8) | 345 (84.8) |
Sequence of radiotherapy with surgery | |||
Pre-operative radiotherapy | 69/254 (27.2) | 37/192 (19.3) | 32/62 (51.6) |
Post-operative radiotherapy | 182/254 (71.7) | 153/192 (79.7) | 29/62 (46.8) |
Intraoperative or sandwich | 3/254 (1.2) | 2/192 (1.0) | 1/62 (1.6) |